In case you missed it, our latest whitepaper provides a practical guide to closing the rare disease product timeline gap; evidence transportability, external control arms, sample-size preservation in real-world evidence, and where to invest early. buff.ly/rlXt6uf
@pharmoinstitute.bsky.social